Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Technologies, CombiMatrix Molecular Diagnostics

Agilent Technologies this week introduced three new microRNA microarray designs: human miRNA microarray v2.0, mouse miRNA microarray v1.0 and rat miRNA microarray v1.0. All three arrays are based on the version 10.1 of the Wellcome-Trust Sanger Institute’s miRBase, updated in December 2007.
The updated human miRNA microarray v2.0 contains 723 human and 76 human viral probe sets. Viral miRNAs are increasingly associated with some cancers, so the firm said it included these probe sets to provide additional value for cancer researchers.
The new mouse miRNA microarray v1.0 contains all known mouse and mouse gamma herpes virus miRNAs. There are 567 mouse and 10 mouse gamma herpes virus distinct probe sets. The new rat miRNA microarray v1.0 contains all 350 known rat miRNA probe sets, Agilent said.
The Agilent miRNA assays are delivered as eight 15,000-feature arrays per standard 1 inch x 3 inch glass slide. The human v2.0 kit, mouse v1.0 kit and rat v1.0 kit are each available as two different pack sizes: one slide with eight arrays or three slides with 24 arrays. The human, mouse and rat miRNA assays are also available as individual slides, each containing eight microarrays.

CombiMatrix Molecular Diagnostics this week launched its BAC HD Scan test, which is designed to interrogate specific genes and genomic regions associated with over 125 known genetic disorders while enabling screening for unexpected abnormalities.
The test uses CMDX’s bacterial artificial chromosome array technology and includes 2,437 unique validated loci obtained through the company's partnership with the Center of Applied Genomics in Toronto. The array also incorporates the probe content of CMDX’s recently launched ATScan test for Autism Spectrum Disorder, CMDX said.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.